Microba Life Sciences (FRA:F3Y) Total Equity: €17.13 Mil (As of Dec. 2025)


FRA:F3Y Microba Life Sciences Ltd FRA:F3Y
29 GF Score
Price €0.02
GF Value €0.12
! 6 Warning Signs
View Full Analysis

What is Microba Life Sciences Total Equity?

Microba Life Sciences FRA:F3Y -2.78% 29 Total Equity is €17.13 Mil as of Dec. 2025. GuruFocus rates FRA:F3Y with a GF Score™ of 29/100 and a GF Value™ of €0.12. The stock has 6 warning signs investors should review.

Microba Life Sciences's total equity for the quarter that ended in Dec. 2025 was €17.13 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Microba Life Sciences Total Equity Historical Data

* Premium members only.

The historical data trend for Microba Life Sciences's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microba Life Sciences Total Equity Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Equity
22.29 23.90 25.43 18.34

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only 30.23 25.43 21.58 18.34 17.13
FRA:F3Y
29GF Score
Microba Life Sciences Ltd FRA:F3Y
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Microba Life Sciences Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Microba Life Sciences's Total Equity for the fiscal year that ended in Jun. 2025 is calculated as

Total Equity=Total Assets(Q: Jun. 2025 )-Total Liabilities(Q: Jun. 2025 )
=26.776-8.435
=18.34

Microba Life Sciences's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=24.601-7.476
=17.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €17.13 Mil mean?
Microba Life Sciences (FRA:F3Y) has a Total Equity of €17.13 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Microba Life Sciences and its competitors.
Is Microba Life Sciences' Total Equity too high?
Microba Life Sciences' current Total Equity is €17.13 Mil. Overall, Microba Life Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Microba Life Sciences' Total Equity compare to TMO and DHR?
Microba Life Sciences' Total Equity of €17.13 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Diagnostics & Research company?
A good Total Equity depends on the Medical Diagnostics & Research industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Microba Life Sciences and its competitors. Microba Life Sciences's current Total Equity is €17.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microba Life Sciences stock overvalued right now?
Microba Life Sciences (FRA:F3Y) has a current Total Equity of €17.13 Mil. The stock's GF Value™ is €0.12, compared to a current price of €0.02 — trading 85.4% below its estimated fair value. The current Total Equity is €17.13 Mil. Microba Life Sciences' overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Microba Life Sciences (FRA:F3Y), the current Total Equity is €17.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?

Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued. The current stock price of €0.02 is trading 85.4% below its estimated GF Value™ of €0.12.

Key valuation signals for FRA:F3Y:

  • Total Equity: €17.13 Mil
  • GF Value™: €0.12 vs. price of €0.02 (85.4% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Microba Life Sciences Business Description

Other Exchanges MAP:Australia
Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score

Get the complete analysis for FRA:F3Y

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.12
GF Value